Stock Analysis

Alligator Bioscience Third Quarter 2024 Earnings: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

OM:ATORX
Source: Shutterstock

Alligator Bioscience (STO:ATORX) Third Quarter 2024 Results

Key Financial Results

  • Revenue: kr2.27m (down 89% from 3Q 2023).
  • Net loss: kr66.5m (loss widened by 27% from 3Q 2023).
  • kr0.08 loss per share.
earnings-and-revenue-growth
OM:ATORX Earnings and Revenue Growth October 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Alligator Bioscience Earnings Insights

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 45% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 7 warning signs for Alligator Bioscience (2 are a bit unpleasant!) that you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:ATORX

Alligator Bioscience

A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.

Medium-low and slightly overvalued.

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|44.027% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|61.937% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.10|70.294% undervalued
StockMan
StockMan
Community Contributor